EA201790547A1 - Новые соединения в качестве ингибиторов реаранжированной во время трансфекции (ret) киназы - Google Patents
Новые соединения в качестве ингибиторов реаранжированной во время трансфекции (ret) киназыInfo
- Publication number
- EA201790547A1 EA201790547A1 EA201790547A EA201790547A EA201790547A1 EA 201790547 A1 EA201790547 A1 EA 201790547A1 EA 201790547 A EA201790547 A EA 201790547A EA 201790547 A EA201790547 A EA 201790547A EA 201790547 A1 EA201790547 A1 EA 201790547A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cancer
- functional
- thyroid
- ret
- carcinoma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyridine Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Настоящее изобретение относится к новым соединениям, которые являются ингибиторами реаранжированной во время трансфекции (RET) киназы, к фармацевтическим композициям, содержащим такие соединения, к способам их получения и к их применению в терапии, отдельно или в комбинации, для нормализации желудочно-кишечной чувствительности, моторики и/или секреции и/или абдоминальных расстройств или заболеваний и/или лечения, связанного с заболеваниями, связанными с дисфункцией RET, или где модуляция RET активности может иметь терапевтическую пользу, включая, но не ограничиваясь этим, все классификации синдрома раздраженной толстой кишки (IBS), включая диарея-преобладающий, запор-преобладающий или с альтернирующим режимом дефекации, функциональное вздутие живота, функциональный запор, функциональную диарею, неуточненное функциональное расстройство пищеварительного тракта, синдром функциональной абдоминальной боли, хронический идиопатический запор, функциональные эзофагеальные расстройства, функциональные расстройства желудка и двенадцатиперстной кишки, функциональные аноректальные боли, воспалительное заболевание кишечника, пролиферативные заболевания, такие как немелкоклеточный рак легкого, гепатоцеллюлярная карцинома, колоректальный рак, медуллярный рак щитовидной железы, фолликулярный рак щитовидной железы, анапластический рак щитовидной железы, папиллярный рак щитовидной железы, опухоли головного мозга, рак перитонеальной полости, солидные опухоли, другой тип рака легкого, рак головы и шеи, глиомы, нефробластомы, синдром фон Гиппеля-Линдау и опухоли почек, рак молочной железы, рак фаллопиевых труб, рак яичника, переходноклеточный рак, рак предстательной железы, рак пищевода и гастроэзофагеального соединения, рак желчных протоков, аденокарцинома и любое злокачественное заболевание с повышенной RET киназной активностью.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2014000834 | 2014-09-10 | ||
PCT/CN2015/089332 WO2016037578A1 (en) | 2014-09-10 | 2015-09-10 | Novel compounds as rearranged during transfection (ret) inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201790547A1 true EA201790547A1 (ru) | 2017-07-31 |
EA032030B1 EA032030B1 (ru) | 2019-03-29 |
Family
ID=55458357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201790547A EA032030B1 (ru) | 2014-09-10 | 2015-09-10 | Соединения в качестве ингибиторов реаранжированной во время трансфекции (ret) киназы |
Country Status (23)
Country | Link |
---|---|
US (2) | US9879021B2 (ru) |
EP (1) | EP3191449B1 (ru) |
JP (1) | JP6538153B2 (ru) |
KR (1) | KR20170046180A (ru) |
CN (1) | CN107250110B (ru) |
AU (1) | AU2015316438B2 (ru) |
BR (1) | BR112017004897A2 (ru) |
CA (1) | CA2960730A1 (ru) |
CL (1) | CL2017000589A1 (ru) |
CO (1) | CO2017002378A2 (ru) |
CR (1) | CR20170094A (ru) |
DK (1) | DK3191449T3 (ru) |
DO (1) | DOP2017000067A (ru) |
EA (1) | EA032030B1 (ru) |
ES (1) | ES2819871T3 (ru) |
IL (1) | IL250923B (ru) |
MX (1) | MX2017003118A (ru) |
MY (1) | MY187169A (ru) |
PE (1) | PE20170677A1 (ru) |
PH (1) | PH12017500454A1 (ru) |
SG (1) | SG11201701695UA (ru) |
UA (1) | UA123084C2 (ru) |
WO (1) | WO2016037578A1 (ru) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3521291A1 (en) | 2010-05-20 | 2019-08-07 | Array Biopharma, Inc. | Macrocyclic compounds as trk kinase inhibitors |
EP3517526B1 (en) | 2014-09-10 | 2020-08-19 | GlaxoSmithKline Intellectual Property Development Limited | Pyridinones as rearranged during transfection (ret) inhibitors |
CR20170094A (es) | 2014-09-10 | 2017-05-08 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret) |
US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
RS61485B1 (sr) | 2015-07-16 | 2021-03-31 | Array Biopharma Inc | Supstituisana pirazolo [1,5-a] piridinska jedinjenja kao inhibitori ret kinaze |
SG11201803653QA (en) | 2015-11-02 | 2018-05-30 | Blueprint Medicines Corp | Inhibitors of ret |
WO2017145050A1 (en) * | 2016-02-23 | 2017-08-31 | Glaxosmithkline Intellectual Property Development Limited | Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer |
CA3016161A1 (en) * | 2016-03-03 | 2017-09-08 | Cornell University | Small molecule ire1-alpha inhibitors |
TW201738228A (zh) | 2016-03-17 | 2017-11-01 | 藍圖醫藥公司 | Ret之抑制劑 |
US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
JP2018052878A (ja) * | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | ピリジン化合物 |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
CA3049136C (en) | 2017-01-18 | 2022-06-14 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
US20210290620A1 (en) | 2017-05-15 | 2021-09-23 | Blueprint Medicines Corporation | Combinations of RET Inhibitors and mTORC1 Inhibitors and Uses Thereof for the Treatment of Cancer Mediated by Aberrant RET Activity |
TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
CA3087354C (en) | 2018-01-18 | 2023-01-03 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
JP7061195B2 (ja) | 2018-01-18 | 2022-04-27 | アレイ バイオファーマ インコーポレイテッド | RETキナーゼ阻害剤としての置換ピラゾロ[3,4-d]ピリミジン化合物 |
US11472802B2 (en) | 2018-01-18 | 2022-10-18 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors |
CA3096043A1 (en) | 2018-04-03 | 2019-10-10 | Blueprint Medicines Corporation | Ret inhibitor for use in treating cancer having a ret alteration |
CN109096264B (zh) * | 2018-08-28 | 2019-08-23 | 山东理工职业学院 | Ret抑制剂及其制备方法、组合物和用途 |
EP3849986B1 (en) | 2018-09-10 | 2022-06-08 | Array Biopharma, Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
WO2020083311A1 (zh) * | 2018-10-24 | 2020-04-30 | 南京明德新药研发有限公司 | 作为ret抑制剂的吡嗪衍生物 |
CN109678724A (zh) * | 2018-12-18 | 2019-04-26 | 常州大学 | 一种2-甲基-1-取代苯基-2-丙胺类化合物的新合成方法 |
CN110950898B (zh) * | 2019-12-12 | 2022-11-11 | 江苏华益科技有限公司 | 一种含氮的氘代甲基化合物的合成方法 |
CN111187257B (zh) * | 2020-02-17 | 2021-03-16 | 山东理工职业学院 | Ret受体酪氨酸激酶抑制剂 |
WO2022017524A1 (zh) * | 2020-07-23 | 2022-01-27 | 深圳晶泰科技有限公司 | 吡啶酮类化合物及其制备方法和应用 |
CA3197220A1 (en) | 2020-11-06 | 2022-05-12 | David Craig Mcgowan | 2-pyridones as thyroid hormone receptor modulators |
CN114539065B (zh) * | 2020-11-25 | 2023-07-25 | 帕潘纳(北京)科技有限公司 | 制备4-硝基-2-三氟甲基苯乙酮的方法 |
WO2022256284A1 (en) | 2021-06-02 | 2022-12-08 | Fmc Corporation | Fused pyridines for controlling invertebrate pests |
CN113896650A (zh) * | 2021-10-27 | 2022-01-07 | 成都科圣原医药科技有限公司 | 一种辛波莫德中间体的合成方法 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070244120A1 (en) * | 2000-08-18 | 2007-10-18 | Jacques Dumas | Inhibition of raf kinase using substituted heterocyclic ureas |
EP1041982B1 (en) | 1997-12-22 | 2011-10-19 | Bayer HealthCare LLC | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS |
US20120046290A1 (en) | 1997-12-22 | 2012-02-23 | Jacques Dumas | Inhibition of p38 kinase activity using substituted heterocyclic ureas |
CN1149085C (zh) * | 1997-12-22 | 2004-05-12 | 拜尔有限公司 | 用取代杂环脲抑制raf激酶 |
KR20020060160A (ko) | 1999-08-12 | 2002-07-16 | 파마시아 이탈리아 에스.피.에이. | 3(5)-아미노-피라졸 유도체, 이의 제조 방법 및항종양제로서의 이의 용도 |
EP1345909A1 (en) | 2000-11-27 | 2003-09-24 | Pharmacia Italia S.p.A. | Phenylacetamido-pyrazole derivatives and their use as antitumor agents |
DE10201764A1 (de) | 2002-01-18 | 2003-07-31 | Bayer Cropscience Ag | Substituierte 4-Aminopyridin-Derivate |
PE20040522A1 (es) * | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
JPWO2004024694A1 (ja) * | 2002-09-10 | 2006-01-05 | 杏林製薬株式会社 | 4−置換アリール−5−ヒドロキシイソキノリノン誘導体 |
AU2004266719A1 (en) | 2003-08-22 | 2005-03-03 | Boehringer Ingelheim France S.A.S. | Methods of treating COPD and pulmonary hypertension |
US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
DK2001892T3 (da) * | 2006-03-17 | 2013-07-01 | Ambit Biosciences Corp | Imidazolthiazolforbindelser til behandling af proliferative sygdomme |
PT2041071E (pt) | 2006-06-29 | 2014-09-23 | Kinex Pharmaceuticals Llc | Composições de biarilo e processos para a regulação de uma cascata de cinases |
MX2009003985A (es) | 2006-10-16 | 2009-04-27 | Novartis Ag | Fenil-acetamidas utiles como inhibidores de cinasa de proteina. |
AU2007321719B2 (en) | 2006-11-15 | 2013-11-21 | Ym Biosciences Australia Pty Ltd | Inhibitors of kinase activity |
CN102470127A (zh) | 2009-08-19 | 2012-05-23 | 埃姆比特生物科学公司 | 联芳基化合物和其使用方法 |
US9073895B2 (en) | 2010-12-16 | 2015-07-07 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
PL2970191T3 (pl) | 2013-03-15 | 2017-07-31 | Glaxosmithkline Intellectual Property Development Limited | Pochodne pirydyny jako inhibitory kinazy przebudowanej podczas transfekcji (RET) |
US8937071B2 (en) | 2013-03-15 | 2015-01-20 | Glaxosmithkline Intellectual Property Development Limited | Compounds as rearranged during transfection (RET) inhibitors |
EP3517526B1 (en) | 2014-09-10 | 2020-08-19 | GlaxoSmithKline Intellectual Property Development Limited | Pyridinones as rearranged during transfection (ret) inhibitors |
CR20170094A (es) | 2014-09-10 | 2017-05-08 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret) |
-
2015
- 2015-09-10 CR CR20170094A patent/CR20170094A/es unknown
- 2015-09-10 CN CN201580060784.XA patent/CN107250110B/zh not_active Expired - Fee Related
- 2015-09-10 US US15/509,569 patent/US9879021B2/en active Active
- 2015-09-10 EA EA201790547A patent/EA032030B1/ru not_active IP Right Cessation
- 2015-09-10 PE PE2017000446A patent/PE20170677A1/es unknown
- 2015-09-10 MX MX2017003118A patent/MX2017003118A/es unknown
- 2015-09-10 AU AU2015316438A patent/AU2015316438B2/en not_active Ceased
- 2015-09-10 EP EP15840612.4A patent/EP3191449B1/en active Active
- 2015-09-10 DK DK15840612.4T patent/DK3191449T3/da active
- 2015-09-10 JP JP2017513448A patent/JP6538153B2/ja not_active Expired - Fee Related
- 2015-09-10 MY MYPI2017700792A patent/MY187169A/en unknown
- 2015-09-10 WO PCT/CN2015/089332 patent/WO2016037578A1/en active Application Filing
- 2015-09-10 CA CA2960730A patent/CA2960730A1/en not_active Abandoned
- 2015-09-10 SG SG11201701695UA patent/SG11201701695UA/en unknown
- 2015-09-10 BR BR112017004897A patent/BR112017004897A2/pt not_active IP Right Cessation
- 2015-09-10 ES ES15840612T patent/ES2819871T3/es active Active
- 2015-09-10 UA UAA201703477A patent/UA123084C2/uk unknown
- 2015-09-10 KR KR1020177009244A patent/KR20170046180A/ko not_active Application Discontinuation
-
2017
- 2017-03-05 IL IL250923A patent/IL250923B/en active IP Right Grant
- 2017-03-09 CL CL2017000589A patent/CL2017000589A1/es unknown
- 2017-03-10 DO DO2017000067A patent/DOP2017000067A/es unknown
- 2017-03-10 CO CONC2017/0002378A patent/CO2017002378A2/es unknown
- 2017-03-10 PH PH12017500454A patent/PH12017500454A1/en unknown
- 2017-12-11 US US15/837,048 patent/US10294236B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DK3191449T3 (da) | 2020-08-03 |
CA2960730A1 (en) | 2016-03-17 |
ES2819871T3 (es) | 2021-04-19 |
CN107250110A (zh) | 2017-10-13 |
AU2015316438B2 (en) | 2018-05-24 |
US10294236B2 (en) | 2019-05-21 |
PE20170677A1 (es) | 2017-05-13 |
SG11201701695UA (en) | 2017-04-27 |
JP2017526711A (ja) | 2017-09-14 |
WO2016037578A1 (en) | 2016-03-17 |
JP6538153B2 (ja) | 2019-07-03 |
AU2015316438A1 (en) | 2017-03-30 |
KR20170046180A (ko) | 2017-04-28 |
US9879021B2 (en) | 2018-01-30 |
CO2017002378A2 (es) | 2017-06-30 |
EP3191449B1 (en) | 2020-07-01 |
EA032030B1 (ru) | 2019-03-29 |
EP3191449A4 (en) | 2018-04-25 |
IL250923A0 (en) | 2017-04-30 |
BR112017004897A2 (pt) | 2017-12-12 |
MY187169A (en) | 2021-09-07 |
PH12017500454A1 (en) | 2017-07-31 |
IL250923B (en) | 2021-04-29 |
EP3191449A1 (en) | 2017-07-19 |
CN107250110B (zh) | 2020-04-24 |
US20180099976A1 (en) | 2018-04-12 |
UA123084C2 (uk) | 2021-02-17 |
DOP2017000067A (es) | 2017-04-16 |
US20170298074A1 (en) | 2017-10-19 |
MX2017003118A (es) | 2018-05-07 |
CR20170094A (es) | 2017-05-08 |
CL2017000589A1 (es) | 2017-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201790547A1 (ru) | Новые соединения в качестве ингибиторов реаранжированной во время трансфекции (ret) киназы | |
CY1121661T1 (el) | Παραγωγα πυριδονης ως αναστολεις της αναδιαταγμενης κατα τη διαμολυνση (ret) κινασης | |
PH12015502044A1 (en) | Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors | |
MA38394A1 (fr) | Dérivés pyridine utilisés comme inhibiteurs de la kinase réarrangée au cours de la transfection (ret) | |
JPWO2019189780A5 (ru) | ||
EA201790404A1 (ru) | Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака | |
WO2015109180A3 (en) | Compositions and methods for treatment and detection of cancers | |
CL2016002359A1 (es) | Anticuerpos que se une al receptor de crecimiento epidermal humano (anti-egfr) y conjugados de anticuerpo anti-egfr y fármaco | |
WO2016123591A3 (en) | Compositions and methods for treatment and detection of cancers | |
NI201700068A (es) | Composiciones anticancerosas | |
JP2017514806A5 (ru) | ||
RU2017115773A (ru) | 17альфа-бензоат кортексолона для применения в лечении опухолей | |
RU2017138468A (ru) | Антитела против человеческого her3, имеющие низкое содержание фукозы, и области их применения | |
JP2018515137A5 (ru) | ||
MX2017011600A (es) | Terapeuticos de anticuerpo que enlazan antigeno de membrana especifico de prostata. | |
WO2014145817A3 (en) | Novel therapeutic target for the treatment of cancers and related therapies and methods | |
MX2021003214A (es) | Metodos terapeuticos y de diagnostico para el cancer de vejiga. | |
EA201892194A1 (ru) | Композиции комплекса трехвалентного железа с мальтолом для применения для лечения или предотвращения рака и опухолей | |
TH158993B (th) | อนุพันธ์ไพริดีนในรูปสารยับยั้งไคเนสถูกจัดเรียงใหม่ในระหว่างการทรานส์เฟคชั่น (ret) | |
Oh et al. | Quantitative proteomics of extracellular vesicles derived from isogenic metastatic and non-metastatic breast cancer in mice models | |
Jokin et al. | CT evaluation of the early and late response of gastrointestinal stromal tumors after Imatinib treatment | |
RU2012157289A (ru) | Способ терапии злокачественной опухоли |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |